The efficacy of Zingiber officinale on dyslipidaemia, blood pressure, and inflammation as cardiovascular risk factors: A systematic review

source extracted confidence: high 2026-04-09
#blood-pressure #c-reactive-protein #cardiovascular-diseases #cholesterol #diabetes-mellitus-type-2

The efficacy of Zingiber officinale on dyslipidaemia, blood pressure, and inflammation as cardiovascular risk factors: A systematic review

Daniels et al., 2022 | Clin Nutr ESPEN | Systematic Review

Citation

Daniels Chelsea Courtney, Isaacs Zaiyaan, ... Leisegang Kristian. The efficacy of Zingiber officinale on dyslipidaemia, blood pressure, and inflammation as cardiovascular risk factors: A systematic review. Clin Nutr ESPEN. 2022-Oct;51:72-82. doi:10.1016/j.clnesp.2022.08.031

Abstract

BACKGROUND & AIMS: Hypertension, dyslipidaemia, and chronic inflammation contribute to the development of cardiovascular disease (CVD). Zingiber officinale has been suggested to reduce these CVD risk factors; however, the clinical evidence remains unclear. This systematic review aims to analyse the effect of Z. officinale as a sole intervention on these risk factors. METHODS: In this PRISMA-based systematic review, we included randomised clinical trials from PubMed, Scopus and Cochrane Database of Systematic Reviews (July 2020) analysing triglycerides, low- and high-density lipoprotein (LDL, HDL), total cholesterol, C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin 1, 6, 10, systolic and/or diastolic blood pressure as outcomes. Quality of studies was evaluated by JADAD and the Cochrane risk-of-bias tools. RESULTS: A total of 24 studies were included, mostly (79.2%) showing low risk of bias. These were based on obesity and cardio-metabolic derangements (33.3%), type 2 diabetes mellitus (37.5%), and miscellaneous conditions (29.2%). While total cholesterol and triglycerides levels mostly improved after Z. officinale, results were inconsistent for other blood lipids markers. Inflammatory markers (CRP, TNF-α) were more consistently reduced by Z. officinale, while only 3 studies reported a non-significant reduction of blood pressure. CONCLUSIONS: Although there remains a paucity of studies, Z. officinale may be beneficial for improving dyslipidaemia and inflammation.

Key Findings

A total of 24 studies were included, mostly (79.2%) showing low risk of bias. These were based on obesity and cardio-metabolic derangements (33.3%), type 2 diabetes mellitus (37.5%), and miscellaneous conditions (29.2%). While total cholesterol and triglycerides levels mostly improved after Z. officinale, results were inconsistent for other blood lipids markers. Inflammatory markers (CRP, TNF-α) were more consistently reduced by Z. officinale, while only 3 studies reported a non-significant redu

Outcomes Measured

  • blood pressure
  • systolic blood pressure
  • diastolic blood pressure
  • C-reactive protein
  • inflammatory markers

Population

Field Value
Population See abstract
Sample Size 24
Age Range See abstract
Condition hypertension

MeSH Terms

  • Blood Pressure
  • C-Reactive Protein
  • Cardiovascular Diseases
  • Cholesterol
  • Diabetes Mellitus, Type 2
  • Dyslipidemias
  • Zingiber officinale
  • Humans
  • Inflammation
  • Interleukin-1
  • Lipids
  • Lipoproteins, HDL
  • Triglycerides
  • Tumor Necrosis Factor-alpha

Evidence Classification

  • Level: Systematic Review
  • Publication Types: Journal Article, Systematic Review
  • Vertical: ginger

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09